An update to rosacea treatment guidelines provides a comprehensive summary of management options, including expert evaluations–based on the phenotypes of each patient–to serve as a guide for tailoring treatment and care.
FMX103 1.5%, a novel topical minocycline foam, proves to be a respectable choice for treatment of moderate to severe papulopustular rosacea.
Compelling evidence supports IVM 1% cream as an effective topical treatment for papulopustular rosacea, that improves QoL over time.
Zinc was found to have beneficial effects on acne vulgaris, atopic dermatitis, diaper dermatitis, and hidradenitis suppurativa in small studies. Psoriasis and rosacea showed no significant benefit of zinc treatment on disease outcome.
Topical treatment with benzyl benzoate and crotamiton may be an effective treatment for rosacea and demodicosis, indirectly supporting a key role of the mite in the pathophysiology of rosacea.
This review gives insight into the role of gut microbiome alterations in the pathogenesis of psoriasis, acne, rosacea, hidradenitis suppurativa, and atopic dermatitis.
Treatment options and concerns unique to patients with skin of color are reviewed.
Effects on self-perception and emotional, social, and overall well-being were significantly greater in patients with severe erythema of rosacea.
Updated recommendations include discussing disease burden with patients during consultations, and having complete clearance as the primary treatment objective.
Superficial needle-scraping can be a useful alternative or addition to standardized skin surface biopsy for evaluation of Demodex-associated facial papulopustular eruptions.
